Clinical Outcomes of Palbociclib and Letrozole in PALOMA-2

Palbociclib plus letrozole clinical outcomes PALOMA-2

In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival by 13 months compared to letrozole alone (27.6 vs 14.5 months) with manageable hematologic toxicity and maintained quality of life, but did not demonstrate a significant overall survival benefit after 90 months of follow-up.

Abstract

The PALOMA-2 trial demonstrated that palbociclib plus letrozole significantly improved progression-free survival compared to placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. Median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), with consistent benefit observed across all patient subgroups including Asian patients (25.7 vs 13.9 months, HR 0.49, P=0.007) and those with low disease burden. Notably, PFS improvement occurred regardless of objective response status, with non-responders experiencing median PFS of 10.9 versus 5.6 months (HR 0.72, P=0.016). The treatment delayed time to subsequent chemotherapy by approximately 10 months (40.4 vs 29.9 months). However, after 90.1 months of follow-up, median overall survival was 53.9 versus 51.2 months (HR 0.96, P=0.34), showing no significant improvement.

The primary toxicity was hematologic, with grade 3-4 neutropenia occurring in 66.4% of patients (vs 1.4% with placebo), increasing to 89.2% in Asian populations. Despite this, febrile neutropenia remained rare (1.8-2.0%), and treatment discontinuation rates were low (9.7-12.2% vs 5.9%). Quality of life was maintained with no significant differences in FACT-Breast Total or EQ-5D scores between treatment arms, and pain scores significantly improved with palbociclib plus letrozole (P=0.0183). Neutropenia did not negatively impact quality of life measures.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Screening

We screened in sources based on their abstracts that met these criteria:

• PALOMA-2 Trial Relevance: Does this study report on the PALOMA-2 trial (NCT01740427) or its secondary/post-hoc analyses?
• Patient Population: Does this study include patients with hormone receptor-positive, HER2-negative advanced breast cancer?
• Clinical Outcomes: Does this study report clinical efficacy outcomes (progression-free survival, overall survival, objective response rate, clinical benefit rate), safety and tolerability outcomes, quality of life analyses, or is it a systematic review/meta-analysis that includes PALOMA-2 data?
• Intervention Specificity: Does this study focus on palbociclib plus letrozole combination therapy (rather than palbociclib with other endocrine partners or palbociclib monotherapy)?
• Disease Population Specificity: Does this study focus on the appropriate breast cancer population (not exclusively triple-negative, HER2-positive, or early-stage disease)?
• Study Design Appropriateness: Is this study a clinical study in humans (not preclinical, in vitro, animal studies, case reports, or case series)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Results

Characteristics of Included Studies

The included publications comprised analyses from the PALOMA-2 trial, a phase 3 randomized controlled trial that enrolled 666 postmenopausal women with ER+/HER2- advanced breast cancer. Patients were randomized 2:1 to palbociclib plus letrozole (n=444) or placebo plus letrozole (n=222). Key eligibility criteria included no prior systemic therapy for advanced disease and performance status 0-2. Disease characteristics at baseline included measurable disease in 76-77% of patients, with approximately 48% having visceral disease and 52% non-visceral disease.

Efficacy Outcomes

• Progression-Free Survival: Across all analyses, palbociclib plus letrozole demonstrated consistent improvement in PFS compared to placebo plus letrozole.
  • Primary analysis: median PFS (24.8 months vs 14.5 months, HR 0.58, 95% CI 0.46-0.72, P<0.001)
  • Extended follow-up: median PFS (27.6 months vs 14.5 months, HR 0.56, P<0.0001)
• Overall Survival: After 90.1 months of follow-up, median OS was 53.9 months (95% CI 49.8-60.8) with palbociclib plus letrozole versus 51.2 months (95% CI 43.7-58.9) with placebo plus letrozole (HR 0.96, P=0.34).
• Objective Response Rate: In the intent-to-treat population, objective response was achieved by 44% of patients receiving palbociclib plus letrozole versus 35% receiving placebo plus letrozole.
• Time to Subsequent Therapy: Palbociclib delayed the use of subsequent therapies (median time to first subsequent therapy: 28.0 vs 17.7 months).

Safety Outcomes

• Hematologic Toxicities: Neutropenia was the most common adverse event, occurring in 66.4% of patients (grade 3-4) in the palbociclib-letrozole arm versus 1.4% in the placebo arm.
• Serious Adverse Events: Serious adverse events were more common in the palbociclib arm (23.6% vs 15.3%). Infections were the most frequently reported serious adverse events.

Patient-Reported Outcomes and Quality of Life

Patient-reported outcomes were assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-Breast) and EuroQol 5 dimensions (EQ-5D) questionnaires. Pain scores improved significantly in the palbociclib plus letrozole arm (-0.256 vs -0.098, P=0.0183).

Clinical Implications

The PALOMA-2 trial consistently demonstrated progression-free survival benefit with palbociclib plus letrozole and maintained quality of life despite the adverse effects. The absence of significant overall survival improvement raises questions about the long-term impact of treatment and reaffirms the importance of managing side effects while retaining treatment efficacy.